Pfizer and BioNTech Complete Dosing of First Group in Coronavirus Vaccine Trial
It was just last week that Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) got permission to start a phase 1/2 clinical trial of BNT162, their SARS-CoV-2 vaccine candidate, in Germany.
Seven days later and the companies have already completed inoculating the first group of patients in the study. Of course, that group only consists of 12 participants -- and there are presumably plenty of people eager to participate given the lack of an approved coronavirus vaccine -- but the speed is still impressive nevertheless.
The safety portion of the clinical trial involves testing a range of doses from 1 microgram to 100 micrograms, and will eventually enroll 200 participants. BioNTech has developed four different variations of its mRNA vaccine. For three of the vaccines, the clinical trial will include booster shots after the initial vaccine to hopefully increase the amount of antibodies the participants generate. The fourth vaccine is a self-amplifying mRNA, so the hope is that only a single dose of the vaccine will be required.
Source Fool.com
